Behavioral and pharmacologic therapy of obstructive sleep apnea

Clinics in Chest Medicine

Volumn 24, Issue 2, 2003, Pages 343-353

  Magalang, Ulysses J ^a,b,d   Mador, M Jeffery ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Associated Sleep Center   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^d ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; FLUOXETINE; MEDROXYPROGESTERONE; MODAFINIL; PAROXETINE; PROGESTERONE; PROTRIPTYLINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; THYROID HORMONE; THYROXINE; TRAZODONE; TRYPTOPHAN;

ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; BODY POSTURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP APNEA SYNDROME; URINE RETENTION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0038532535     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00022-4     Document Type: Review

References (92)

1. Grunstein R, Wilcox I, Yang TS, et al. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord 1993;22:39-47.
2. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle aged adults. N Engl J Med 1993;328:1230-5.
3. Strobel RJ, Rosen RC. Obesity and weight loss in obstructive sleep apnea: a critical review. Sleep 1996;19:104-15.
4. Haponik E, Smith P, Bohlman M, et al. Computerized tomography in obstructive sleep apnea: correlation of airway size with physiology during sleep and wakefulness. Am Rev Respir Dis 1983;127:221-6.
5. Schwab R, Gefter W, Hoffman E, et al. Dynamic upper airway imaging during awake respiration in normal subjects and patients with sleep disordered breathing. Am Rev Respir Dis 1993;148:1385-400.
6. Horner R, Mohiaddin R, Lowell D, et al. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. Eur Respir J 1989;2:613-22.
7. Brown I, McClean P, Boucher R, et al. Changes in pharyngeal cross sectional area with posture and application of continuous positive airway pressure in patients with obstructive sleep apnea. Am Rev Respir Dis 1987;136:628-32.
8. Suratt P, McTier R, Findley L, et al. Collapsibility of the nasopharyngeal airway in obstructive sleep apnea. Am Rev Respir Dis 1985;132:967-71.
9. Schwartz AR, Gold AR, Schubert N, et al. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. Am Rev Respir Dis 1991;144:494-8.
10. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep disordered breathing. JAMA 2000;284:3015-21.
11. Smith PL, Gold AR, Meyers DA, et al. Weight loss in mildly to moderately obese patients with obstructive sleep apnea. Ann Intern Med 1985;103:850-5.
12. Rubinstein I, Colapinto N, Rotstein L, et al. Improvement in upper airway function after weight loss in patients with obstructive sleep apnea. Am Rev Respir Dis 1988;138:1192-5.
13. Kiselak J, Clark M, Pera V, et al. The association between hypertension and sleep apnea in obese patients. Chest 1993;104:775-80.
14. Suratt P, McTier R, Findley L, et al. Effect of very-low calorie diets with weight loss on obstructive sleep apnea. Am J Clin Nutr 1992;56:182S-4S.
15. Rajala R, Partinen M, Sane T, et al. Obstructive sleep apnea in morbidly obese patients. J Intern Med 1991;230:125-9.
16. Lojander J, Mustajoki P, Ronka S, et al. A nurse-managed weight reduction programme for obstructive sleep apnoea syndrome. J Intern Med 1998;244:251-5.
17. Kansanen M, Vanninen E, Tuunainen A, et al. The effect of very low-calorie diet-induced weight loss on the severity of obstructive sleep apnoea and autonomic nervous function in obese patients with obstructive sleep apnoea syndrome. Clin Physiol 1998;18:377-85.
18. Pasquali R, Colella P, Cirignotta F, et al. Treatment of obese patients with obstructive sleep apnea syndrome (OSAS): effect of weight loss and interference of otorhinolaryngoiatric pathology. Int J Obes 1990;14:207-17.
19. Peiser J, Lavie P, Ovnat A, et al. Sleep apnea syndrome in the morbidly obese as an indication for weight reduction surgery. Ann Surg 1984;199:112-5.
20. Sugerman HJ, Fairman RP, Sood RK, et al. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr 1992;55:597S-601S.
21. Harman EM, Wynne JW, Block AJ. The effect of weight loss on sleep disordered breathing and oxygen desaturation in morbidly obese men. Chest 1982;82:291-4.
22. Charuzi I, Ovnat A, Peiser J, et al. The effect of surgical weight reduction on sleep quality in obesity-related sleep apnea syndrome. Surgery 1985;97:535-8.
23. Scheuller M, Weider D. Bariatric surgery for treatment of sleep apnea syndrome in 15 morbidly obese patients: long-term results. Otolaryngol Head Neck Surg 2001;125:299-302.
24. Pillar G, Peled R, Lavie P. Recurrence of sleep apnea without concomitant weight increase 7.5 years after weight reduction surgery. Chest 1994;106:1702-4.
25. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
26. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89.
27. Shneerson J, Wright J. Lifestyle modification for obstructive sleep apnoea. Cochrane Database of Systematic Reviews 2002;4.
28. NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann Intern Med 1993;119:764-70.
29. Garner D, Wooley S. Confronting the failure of behavioural and dietary treatment for obesity. Clin Psychol Rev 1991;11:729-80.
30. Sampol G, Munoz X, Sagales MT, et al. Long-term efficacy of dietary weight loss in sleep apnoea/hypopnoea syndrome. Eur Respir J 1998;12:1156-9.
31. Oksenberg A, Silverberg DS, Arons E, et al. Positional vs nonpositional obstructive sleep apnea patients: anthropomorphic, nocturnal polysomnographic, and multiple sleep latency test data. Chest 1997;112:629-39.
32. Cartwright RD. Effect of sleep position on sleep apnea severity. Sleep 1984;7:110-4.
33. McEvoy RD, Sharp DJ, Thornton AT. The effects of posture on obstructive sleep apnea. Am Rev Respir Dis 1986;133:662-6.
34. Oksenberg A, Khamaysi I, Silverberg DS, et al. Association of body position with severity of apneic events in patients with severe nonpositional obstructive sleep apnea. Chest 2000;118:1018-24.
35. Cartwright R, Ristanovic R, Diaz F, et al. A comparative study of treatments for positional sleep apnea. Sleep 1991;14:546-52.
36. Cartwright R, Lloyd S, Lilie J, et al. Sleep position training as treatment for sleep apnea syndrome: a preliminary study. Sleep 1985;8:87-94.
37. Jokic R, Klimaszewski A, Croosley M, et al. Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome. Chest 1999;115:771-81.
38. Jan MA, Marshall I, Douglas NJ. Effect of posture on upper airway dimensions in normal human. Am J Respir Crit Care Med 1994;149:145-8.
39. Martin SE, Marshall I, Douglas NJ. The effect of posture on airway calibre with the sleep-apnea/hypopnea syndrome. Am J Respir Crit Care Med 1995;152:721-4.
40. Neill AM, Angus SM, Sajkov D, et al. Effects of sleep posture on upper airway stability in patients with obstructive sleep apnea. Am J Respir Crit Care Med 1997;155:199-204.
41. Penzel T, Moller M, Becker HF, et al. Effect of sleep position and sleep stage on the collapsibility of the upper airways in patients with sleep apnea. Sleep 2001;24:909-95.
42. Jokic R, Klimaszewski A, Croosley M, et al. Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome. Chest 1999;115:771-81.
43. Remmers JE, Degroot WJ, Sauerland EK, et al. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol 1978;44:931-8.
44. Hudgel DW, Thanakitcharu S. Pharmacologic treatment of sleep-disordered breathing. Am J Respir Crit Care Med 1998;158:691-9.
45. Brownell LG, West P, Sweatman P, et al. Protriptyline in obstructive sleep apnea. N Engl J Med 1982;307:1037-42.
46. Whyte KF, Gould GA, Airlie MAA, et al. Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep 1988;11:463-72.
47. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991;100:416-21.
48. Smith PL, Haponik EF, Allen RP, et al. The effects of protriptyline in sleep-disordered breathing. Am Rev Respir Dis 1983;127:8-13.
49. Conway WA, Zorck F, Piccione P, et al. Protriptyline in the treatment of sleep apnoea. Thorax 1982;37:49-53.
50. Bonora M, St. John WM, Beldsoe TA. Differential elevation by protriptyline and depression by diazepam of upper airway respiratory muscle activity. Am Rev Respir Dis 1985;131:41-5.
51. Strohl KP, Hensley NJ, Saunders NA, et al. Progesterone administration and progressive sleep apnea. JAMA 1981;245:1230-2.
52. Orr WC, Imes NK, Martin RJ. Progesterone therapy in obese patients with sleep apnea. Arch Intern Med 1979;139:109-11.
53. Rajagopal KR, Abbrecht PH, Jabbari B. Effects of medroxyprogesterone acetate in obstructive sleep apnea. Chest 1986;90:815-21.
54. Cistulli PA, Barnes DJ, Grunstein RR, et al. Effect of short term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax 1994;49:699-702.
55. Cook WR, Benich JJ, Wooten SA. Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989;96:262-6.
56. Sutton FD, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975;83:476-9.
57. Lin CC, Tsan KW, Chen PJ. The relationship between sleep apnea syndrome and hypothyroidism. Chest 1994;105:1296-7.
58. Grunstein RR, Sullivan CE. Sleep apnea and hypothyroidism: mechanisms and management. Am J Med 1988;85:775-9.
59. Rajagopal KR, Abbrecht PH, Derderian SS, et al. Obstructive sleep apnea in hypothyroidism. Ann Intern Med 1984;101:491-4.
60. Pelttari L, Rauhala E, Polo O, et al. Upper airway obstruction in hypothyroidism. J Intern Med 1994;236:177-81.
61. Orr WC, Males JL, Imes NK. Myxedema and obstructive sleep apnea. Am J Med 1981;70:1061-6.
62. Skatrud J, Iber C, Ewart R, et al. Disordered breathing during sleep in hypothyroidism. Am Rev Respir Dis 1981;124:325-9.
63. Skjodt NM, Atkar R, Easton PA. Screening for hypothyroidism in sleep apnea. Am J Respir Crit Care Med 1999;160:732-5.
64. Winkelman JW, Goldman H, Piscatelli N, et al. Are thyroid function tests necessary in patients with suspected sleep apnea? Sleep 1996;19:790-3.
65. Kapur VK, Koepsell TD, deMaine J, et al. Association of hypothyroidism and obstructive sleep apnea. Am J Respir Crit Care Med 1998;158:1379-83.
66. Berger AJ, Bayliss DA, Viana F. Modulation of neonatal rat hypoglossal motoneuron excitability by serotonin. Neurosci Lett 1992;143:164-8.
67. Kubin L, Tojima H, Davies RO, et al. Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci Lett 1992;139:243-8.
68. Veasey SC, Panckeri KA, Hoffman EA, et al. The effects of serotonin antagonists in an animal model of sleep-disordered breathing. Am J Respir Crit Care Med 1996;153:776-86.
69. Veasey SC, Fenik P, Panckeri KA, et al. The effects of trazodone with L-tryptophan on sleep-disordered breathing in the English bulldog. Am J Respir Crit Care Med 1999;160:1659-67.
70. Sunderram J, Parisi RA, Stobel RJ. Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000;162:925-9.
71. Berry RB, Yamura EM, Gill K, et al. Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 1999;22:1087-92.
72. Schmidt HS. L-tryptophan in the treatment of impaired respiration in sleep. Bull Eur Physiopathol Respir 1983;19:625-9.
73. Kraiczi H, Hedner J, Dahlof P, et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999;22:61-7.
74. Hoyer D, Martin G. 5HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997;36:419-28.
75. Hoyer D, Martin GR. Classification and nomenclature of 5 HT receptors: a comment on current issues. Behav Brain Res 1996;73:263-8.
76. Fuller RW. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res 1995;45:167-204.
77. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229.
78. Woch G, Davies RO, Pack AI, et al. Behaviour of raphe cells projecting to the dorsomedial medulla during carbachol-induced atonia in the cat. J Physiol 1996;490:745-58.
79. Yamuy J, Fung SJ, Xi M, et al. Hypoglossal motoneurons are postsynaptically inhibited during carbachol-induced rapid eye movement sleep. Neuroscience 1999;94:11-5.
80. Guilleminault C, Hayes B. Naloxone, theophylline, bromocriptine, and obstructive sleep apnea: negative results. Bull Eur Physiopathol Respir 1983;19:632-4.
81. Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnea: a double blind evaluation. Chest 1992;101:753-7.
82. Davila DG, Hunt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994;150:469-74.
83. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164:1675-81.
84. Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001;163:918-23.
85. Besset A, Cherit M, Carlander B, et al. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996;26:60-6.
86. Jasinski DR. An evaluation of the abuse potential of modafinil using methyphenidate as a reference. J Psychopharmacol 2000;14:53-60.
87. Black J. Pro: Modafinil has a role in management of sleep apnea. Am J Respir Crit Care Med 2003;167:105-6.
88. Arnulf I, Homeyer P, Garma L, et al. Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 1997;64:159-61.
89. Heitmann J, Cassel W, Grote L, et al. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? Clin Pharmacol Ther 1999;65:328-35.
90. Pollak CP. Con: Modafinil has no role in management of sleep apnea. Am J Respir Crit Care Med 2003;167:106-7.
91. McArdle N, Devereux G, Heidamejad H, et al. Longterm use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:1108-14.
92. Smith I, Lasserson T, Wright J. Drug treatments for obstructive sleep apnea. Cochrane Database of Systematic Reviews 2002;4.